Indoco Remedies is currently trading at Rs. 307.40, up by 5.95 points or 1.97% from its previous closing of Rs. 301.45 on the BSE.
The scrip opened at Rs. 312.90 and has touched a high and low of Rs. 317.80 and Rs. 300.10 respectively. So far 5283 shares were traded on the counter.
The BSE group 'B' stock of face value Rs. 2 has touched a 52 week high of Rs. 416.95 on 01-Jan-2024 and a 52 week low of Rs. 286.50 on 04-Jun-2024.
Last one week high and low of the scrip stood at Rs. 330.60 and Rs. 298.00 respectively. The current market cap of the company is Rs. 2827.69 crore.
The promoters holding in the company stood at 58.75%, while Institutions and Non-Institutions held 19.94% and 21.30% respectively.
Indoco Remedies has received final Abbreviated New Drug Application (ANDA) approval from United States Food and Drug Administration (USFDA) for Varenicline Tablets, 0.5 mg and 1 mg, to market a generic equivalent to the reference listed drug (RLD), Chantix Tablets, 0.5 mg and 1 mg, of PF Prism C.V. (PF).
Varenicline Tablets, 0.5 mg and 1 mg bioequivalent and therapeutically equivalent to the reference listed drug (RLD), Chantix Tablets, 0.5 mg and 1 mg, of PF Prism C.V. (PF). This product, Varenicline Tablets, 0.5 mg and 1 mg will be manufactured by Indoco Remedies, at their manufacturing facility located at L-14, Verna Industrial Area, Verna, Goa in India. Varenicline is used to aid smoking cessation treatment.
Indoco Remedies is engaged in the manufacturing and marketing of formulations (finished dosage forms) and active pharmaceutical ingredients (APIs) in India.
Company Name | CMP |
---|---|
Sun Pharma Inds. | 1808.50 |
Dr. Reddys Lab | 1342.45 |
Cipla | 1472.45 |
Lupin | 2147.55 |
Zydus Lifesciences | 973.90 |
View more.. |